Department of Neurology, Henry Ford Health System, Detroit, MI, USA.
Biostatistics, Henry Ford Health System, Detroit, MI, USA.
J Neurol Sci. 2022 Aug 15;439:120314. doi: 10.1016/j.jns.2022.120314. Epub 2022 Jun 3.
Apathy remains a disabling symptom in Parkinson's disease (PD) with limited therapeutic success. Processing of emotions and smell share neuroanatomical and evolutionary pathways.
To explore the association of apathy with smell dysfunction (SD) in early PD.
We analyzed patients with de-novo PD, with follow-up of at least 5 years from the Parkinson's Progression Markers Initiative. SD and apathy were defined using University of Pennsylvania Smell Identification Test and MDS-UPDRS part 1A. Odds ratios were calculated between apathy and olfaction groups. Kaplan-Meier survival analysis was grouped by presence/ absence of smell dysfunction. The Log Rank test was used to compare time to apathy.
We found no association between presence of apathy in patients with and without SD (OR 1.01 [0.49-2.08]). There was no significant difference between PD patients with and without SD in time to apathy (p = 0.72).
SD does not portend greater risk of apathy in PD.
淡漠仍然是帕金森病（PD）的一种致残症状，治疗效果有限。情绪处理和嗅觉共享神经解剖和进化途径。
探讨早期 PD 中淡漠与嗅觉功能障碍（SD）的关系。
我们分析了帕金森进展标志物倡议中至少有 5 年随访的新发 PD 患者。使用宾夕法尼亚大学嗅觉识别测试和 MDS-UPDRS 第 1A 部分来定义 SD 和淡漠。在淡漠和嗅觉组之间计算了优势比。根据是否存在嗅觉功能障碍对 Kaplan-Meier 生存分析进行分组。对数秩检验用于比较出现淡漠的时间。
我们没有发现 SD 患者和无 SD 患者中存在淡漠的患者之间存在关联（OR 1.01 [0.49-2.08]）。SD 患者和无 SD 患者出现淡漠的时间无显著差异（p=0.72）。
SD 并不能预示 PD 中淡漠的风险更大。
